ReviewCurrent urology reports2018
Pharmacotherapy for Nocturia.
Review in Current urology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Efficacy of novel βInternational journal of urology : official journal of the Japanese Urological Association · 2019Trial
- Effect of Traditional Chinese Medicine External Treatment in Older Patients with Nocturia: A Meta-analysis : Short title: Traditional Chinese Medicine External Therapy for Elderly Nocturia.Galen medical journal · 2026Article
- Effects ofFood science & nutrition · 2025Article
- Coexistence of Nocturia and Frailty and Its Effect on Polypharmacy in Community-Dwelling Older Adults.Cureus · 2025Article
- Effectiveness and Safety of a Mixture of Nobiletin and Tangeretin in Nocturia Patients: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study.Journal of clinical medicine · 2023Article
- Effectiveness of acupuncture for nocturia: A protocol for systematic review and meta-analysis.Medicine · 2021Article
- Comorbidities, Age, and Polypharmacy Limit the Use by US Older Adults with Nocturia of the Only FDA-approved Drugs for the Symptom.Clinical therapeutics · 2020Article
- Urinary metabolites identified using metabolomic analysis as potential biomarkers of nocturia in elderly men.World journal of urology · 2020Observational
- Polysomnography and Nocturia Evaluations after Uvulopalatopharyngoplasty for Obstructive Sleep Apnea Syndrome.Journal of clinical medicine · 2020Article
- New drugs are not enough‑drug repositioning in oncology: An update.International journal of oncology · 2020Review
- Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines.Central European journal of urology · 2020Review
- Nocturia, nocturnal polyuria, and nocturnal enuresis in adults: What we know and what we do not know.Tzu chi medical journalReview
- Pharmacologic management of nocturnal polyuria: a contemporary assessment of efficacy, safety, and progress toward individualized treatment.Therapeutic advances in urologyReview
- Metabolomics analysis of blood identifies potential biomarkers and possible treatment targets for nocturia.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo assess current pharmacological principles used for treatment of nocturia/nocturnal polyuria. RECENT
findingsThe pathophysiology of nocturia is often multifactorial, but two main mechanisms have been identified, occurring alone or in combination: low functional bladder capacity and nocturnal polyuria. The multifactorial pathophysiology not only implies several possible targets for therapeutic intervention but also means that it is unlikely that one treatment modality including drugs will be successful in all patients. Drugs approved for the treatment of male LUTS and male and female OAB are known to be far more effective for treatment of the daytime symptoms than for nocturia. Several pharmacological principles have been tested with varying success. The treatment of choice should depend upon the main underlying cause, thus aiming primarily to increase bladder capacity by counteracting detrusor overactivity and/or reducing nocturnal polyuria. Using current available agents, effective, personalized treatment should be designed taking into account gender, co-morbidities, and identified etiological factors. However, there is a medical need for new, approved drugs for treatments for patients with nocturia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.